Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

464 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pembrolizumab in patients with rare and ultra-rare sarcomas (AcSé Pembrolizumab): analysis of a subgroup from a non-randomised, open-label, phase 2, basket trial.
Blay JY, Chevret S, Le Cesne A, Brahmi M, Penel N, Cousin S, Bertucci F, Bompas E, Ryckewaert T, Soibinet P, Boudou-Rouquette P, Saada Bouzid E, Soulie P, Valentin T, Lotz JP, Tosi D, Neviere Z, Cancel M, Ray-Coquard I, Gambotti L, Legrand F, Lamrani-Ghaouti A, Simon C, Even C, Massard C. Blay JY, et al. Among authors: massard c. Lancet Oncol. 2023 Aug;24(8):892-902. doi: 10.1016/S1470-2045(23)00282-6. Epub 2023 Jul 7. Lancet Oncol. 2023. PMID: 37429302 Clinical Trial.
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.
Chevreau C, Massard C, Flechon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Fizazi K, Mourey L, Paci A, Guitton J, Thomas F, Lelièvre B, Ciccolini J, Moeung S, Gallois Y, Olivier P, Culine S, Filleron T, Chatelut E. Chevreau C, et al. Among authors: massard c. Cancer Med. 2021 Apr;10(7):2250-2258. doi: 10.1002/cam4.3687. Epub 2021 Mar 5. Cancer Med. 2021. PMID: 33675184 Free PMC article. Clinical Trial.
Early phase trials in soft-tissue sarcomas: clinical benefit of inclusion in early lines of treatment, molecular screening, and histology-driven trials.
Nassif EF, Blay JY, Massard C, Dufresne A, Brahmi M, Cassier P, Ray-Coquard I, Pautier P, Leary A, Sunyach MP, Bahleda R, Levy A, Le Pechoux C, Honoré C, Mir O, Le Cesne A. Nassif EF, et al. Among authors: massard c. ESMO Open. 2022 Apr;7(2):100425. doi: 10.1016/j.esmoop.2022.100425. Epub 2022 Mar 5. ESMO Open. 2022. PMID: 35255445 Free PMC article.
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 study.
Baldini C, Charton E, Schultz E, Auroy L, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Le Gouill S, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Roca CG, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Baldini C, et al. Among authors: massard c. ESMO Open. 2022 Jun;7(3):100468. doi: 10.1016/j.esmoop.2022.100468. Epub 2022 May 6. ESMO Open. 2022. PMID: 35533427 Free PMC article.
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 study.
Charton E, Baldini C, Fayet Y, Schultz E, Auroy L, Vallier E, Italiano A, Robert M, Coquan E, Isambert N, Moreau P, Touzeau C, Le Tourneau C, Ghrieb Z, Kiladjian JJ, Delord JP, Gomez Roca C, Vey N, Barlesi F, Lesimple T, Penel N, Soria JC, Massard C, Besle S. Charton E, et al. Among authors: massard c. ESMO Open. 2023 Aug;8(4):101610. doi: 10.1016/j.esmoop.2023.101610. Epub 2023 Aug 1. ESMO Open. 2023. PMID: 37536254 Free PMC article.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Among authors: massard c. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
An international phase II trial and immune profiling of SBRT and atezolizumab in advanced pretreated colorectal cancer.
Levy A, Morel D, Texier M, Sun R, Durand-Labrunie J, Rodriguez-Ruiz ME, Racadot S, Supiot S, Magné N, Cyrille S, Louvel G, Massard C, Verlingue L, Bouquet F, Bustillos A, Bouarroudj L, Quevrin C, Clémenson C, Mondini M, Meziani L, Tselikas L, Bahleda R, Hollebecque A, Deutsch E. Levy A, et al. Among authors: massard c. Mol Cancer. 2024 Mar 23;23(1):61. doi: 10.1186/s12943-024-01970-8. Mol Cancer. 2024. PMID: 38519913 Free PMC article. Clinical Trial.
464 results